Skip to main content

Log In Create an account

Products & Services
Back
Explore
- About Our Products & Services
- Our Tests
  Back
  Our Tests
  
  Compare Our Tests
  
  FoundationOne CDx
  
  FoundationOne Liquid CDx
  
  Real-Life Results
  
  FoundationOne Heme
  
  IHC Testing
- Provider Services
  Back
  Provider Services
  
  Overview
  
  Digital Reporting Experience, Online Ordering, & System Integrations
  
  Clinical Research & Trial Matching
  
  Decision Support & Provider Education
- Biopharma Partner Services
  Back
  Biopharma Partner Services
  
  Overview
  
  Discovery & Translational Research
  
  Clinical Development & CDx
  
  Access & Commercialization
- Actionable Results
Resource Center
Back
Explore
News & Events
Back
Explore
Useful Information
About Us
Back
About Us
Useful Information
Careers
For Patients
Order a Test

ASCO 2023: Informing Outcomes Through ctDNA Monitoring

Abstract:

Abstract 9075: Circulating tumor DNA (ctDNA) monitoring to inform maintenance outcomes in patients (pts) with advanced NSCLC treated with induction atezolizumab+carboplatin+nab-paclitaxel (A+CnP)

This research was presented at the 2023 ASCO Annual Meeting. View all abstracts on asco.org

May 26, 2023

Blog Subscription

Get Notified About New Articles

Products & Services
Our Tests
Provider Services
Biopharma Partner Services

News & Events
Press Releases
Blog
Events
Media Library

About Us
Our Story
Leadership Team
Careers

Contact Us
Login
Order a Test

© 2023 FOUNDATION MEDICINE, INC.

Do Not Sell/Share My Information
California Compliance
Privacy & Website Policies
HIPAA Notice of Privacy Practices
Licenses
Update Cookie Preferences

We noticed you are browsing from outside the United States of America (USA)

The information presented on this website is intended for healthcare professionals, patients, and caregivers located in the USA. To view information intended for users located outside of the USA, please visit our international website, www.rochefoundationmedicine.com. For biopharma partner information, please continue to the US site.

Visit International Site